Denali Therapeutics Inc. (DNLI) News
Filter DNLI News Items
DNLI News Results
|Loading, please wait...|
DNLI News Highlights
- For DNLI, its 30 day story count is now at 31.
- Over the past 24 days, the trend for DNLI's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- CNS, DRUG and LH are the most mentioned tickers in articles about DNLI.
Latest DNLI News From Around the Web
Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
No summary available.
Baron Funds, an asset management firm, published its “Baron Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.
As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI ) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinical hold. Denali has now received a formal clinical Full story available on Benzinga.com
As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinical hold. Denali has now received a formal clinical hold letter and is moving forward to address the FDA's observations related to the preclinical toxicology assessment. The Company will also provide the information requested to initiate clinical studies, including proposed changes to the clinical
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Laboratory (LH – Research Report), Marinus (MRNS – Research Report) and Denali Therapeutics (DNLI – Research Report) with bullish sentiments. Laboratory (LH) Jefferies analyst Brian Tanquilut maintained a Buy rating on Laboratory yesterday and set a price target of $330.00. The company's shares closed last Thursday at $282.19. According to TipRanks.
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price target of $105.00. The company's shares closed last Thursday at $36.27, close to its 52-week low of $30.25. According to TipRanks.com, Fein is a 1-star analyst with an average return of -0.9% and a 38.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Global Blood Therapeutics. Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $90.00.
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that new longer-term data from an ongoing Phase 1/2 clinical trial of DNL310 (ETV:IDS) are being presented today at WORLD Symposium . DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome).
Losers page, we’ve identified the top 5 pre-market stock movers below. 5 Biggest Movers Peloton Interactive, Inc. (PTON), the American exercise equipment and media company, was the biggest laggard in pre-market trading. It lost around 13.6% at the time of writing, reflecting investors’ concerns following the company’s revelation that CEO John Foley will step down and around 2,800 employees will be laid off.